Full Press Release Details
NEWS RELEASE - REGULATED INFORMATION
25 May 2023, 22:30 CET
MDxHealth Announces Results of its Annual and
General Shareholders' Meetings
IRVINE, CA, and HERSTAL, BELGIUM -
25 May 2023 - MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) ("MDxHealth"
or the "Company"), a commercial-stage precision diagnostics company, today held its ordinary annual general shareholders'
meeting ("AGM") and an extraordinary general shareholders' meeting ("EGM").
The items on the agenda of the AGM included the
approval of a number of resolutions relating to the financial year ended on 31 December 2022, as well as the renewal of board mandates.
There was no attendance quorum for the AGM, and the proposed resolutions that were submitted to the meeting were all duly passed.
As the required attendance quorum for the EGM
was not met, a new EGM will be held on Friday 30 June 2023 (unless decided otherwise by the Company). There will be no attendance quorum
for this second EGM.
The minutes of the AGM and documents that were
submitted to the meetings can be accessed via the Company's website.
mdxhealth is a commercial-stage precision diagnostics
company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company's tests are based
on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis
of urologic cancers and other urologic diseases. The Company's U.S. headquarters and laboratory operations are in Irvine, California,
with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen,
and linkedin.com/company/mdxhealth.
For more information:
LifeSci Advisors (IR & PR)
mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks
or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.